A Comprehensive Monograph on Methimazole (Thiamazole)

Section 1: Introduction and Therapeutic Overview

1.1. Executive Summary

Methimazole, known internationally as thiamazole, is a small-molecule drug belonging to the thionamide class of antithyroid agents.[1] It serves as a cornerstone in the medical management of hyperthyroidism by potently inhibiting the synthesis of thyroid hormones within the thyroid gland.[1] In contemporary clinical practice, methimazole is established as the first-line pharmacotherapeutic option for the majority of patients with hyperthyroidism, including those with Graves' disease and toxic multinodular goiter.[3] Its prominence is largely attributable to a more favorable safety profile concerning severe hepatotoxicity when compared to the alternative thionamide, propylthiouracil (PTU), particularly in the pediatric population.[1] While highly effective, the therapeutic application of methimazole requires a nuanced understanding of its potential for rare but serious adverse effects, most notably agranulocytosis and first-trimester teratogenicity, which dictate specific clinical guidelines for its use.

1.2. Historical Context and Regulatory Status

Methimazole has a long and established history in clinical medicine, having first received approval for medical use in the United States in 1950.[7] This extensive period of clinical application has resulted in a well-characterized efficacy and safety profile, solidifying its role in endocrinology. Manufactured by Pfizer Inc. under brand names such as Tapazole, its global importance is further underscored by its inclusion on the World Health Organization's List of Essential Medicines.[3] The drug is available as a generic medication, ensuring broad accessibility for patients requiring treatment for hyperthyroidism.[7]

1.3. Comparative Therapeutic Positioning

The management of hyperthyroidism involves several modalities, including medical therapy with antithyroid drugs, radioactive iodine (RAI) ablation, and surgical thyroidectomy.[9] Methimazole represents the primary agent for medical management. Its selection and duration of use are determined through a careful risk-benefit analysis that considers the patient's specific condition, comorbidities, age, and personal preferences.

The therapeutic landscape for thionamides was fundamentally altered by regulatory actions concerning propylthiouracil. Post-marketing surveillance revealed that PTU is associated with a significant risk of severe, and sometimes fatal, liver injury, particularly in children.[6] This led the U.S. Food and Drug Administration (FDA) to add a black box warning to the PTU label, explicitly recommending that it be reserved for patients who cannot tolerate other treatments, such as methimazole.[6] While methimazole is also associated with hepatotoxicity, the risk is considered substantially lower.[5] Consequently, the pronounced negative safety signal for PTU created a clinical imperative for a safer first-line agent, a role that methimazole has since filled for most patient populations. This dynamic positions methimazole not only on its own merits—including its potency, which on a weight basis is 10 times greater than that of PTU—but also as the beneficiary of its primary alternative's safety concerns.[1] The notable exception to this positioning is in the first trimester of pregnancy, where methimazole's known teratogenic potential leads to a recommendation for PTU.[11]

Section 2: Chemical Identity and Physicochemical Properties

2.1. Nomenclature and Synonyms

The drug is identified by several names globally. The United States Adopted Name (USAN) is Methimazole, while the International Nonproprietary Name (INN) is Thiamazole.[7] It is marketed under various brand names, including Tapazole, Northyx, Favistan, and Danantizol.[3] Chemically, it is referred to by its IUPAC name, 1-methyl-1,3-dihydro-2H-imidazole-2-thione, and other synonyms such as 1-Methylimidazole-2-thiol and Mercazolyl.[1] It is critical to avoid confusion with similarly named but pharmacologically distinct medications like metamizole, methazolamide, or methazole.[7]

2.2. Chemical Structure and Formula

Methimazole is a cyclic thiourea derivative and a member of the imidazole class of compounds.[7] Structurally, it is defined as an imidazole-2-thione in which a methyl group is attached to one of the nitrogen atoms.[1] The molecule consists of a five-membered imidazole ring containing a methyl group at position 1 and a thione (C=S) group at position 2.[2] Its molecular formula is

C4​H6​N2​S.[7]

2.3. Physicochemical Characteristics

In its solid state, methimazole is a white to matte brown crystalline powder with a characteristic odor.[3] It has a defined melting point of 146–148 °C and a boiling point of approximately 280 °C, at which it undergoes decomposition.[3] Its solubility profile is a key determinant of its formulation and absorption. It is soluble in water (275 mg/mL at 20 °C), ethanol, and chloroform, but is only sparingly or slightly soluble in ether and petroleum ether.[1]

Table 1: Summary of Physicochemical Properties and Identifiers

Property/Identifier	Value	Source(s)
DrugBank ID	DB00763	1
CAS Number	60-56-0	1
ATC Codes	H03BB02, H03BB52	7
IUPAC Name	1-methyl-1,3-dihydro-2H-imidazole-2-thione	7
Synonyms	Thiamazole, Tapazole, 1-Methyl-3H-imidazole-2-thione	1
Molecular Formula	C4​H6​N2​S	7
Molar Mass	114.17 g·mol⁻¹	1
Appearance	White to matte brown crystalline powder	7
Melting Point	146 °C (295 °F)	7
Boiling Point	280 °C (decomposition)	3
Solubility in Water	275 mg/mL (at 20 °C)	7
Other Solubilities	Soluble in ethanol, chloroform; sparingly soluble in ether	1
SMILES	Cn1cc[nH]c1=S	7
InChIKey	PMRYVIKBURPHAH-UHFFFAOYSA-N	1

Section 3: Pharmacology and Mechanism of Action

3.1. Primary Mechanism: Inhibition of Thyroperoxidase (TPO)

The central therapeutic effect of methimazole is derived from its potent and irreversible inhibition of thyroperoxidase (TPO), the pivotal enzyme in the biosynthesis of thyroid hormones.[2] TPO is a heme-containing enzyme located in the apical membrane of thyroid follicular cells that catalyzes two critical steps in thyroid hormone synthesis: the iodination of tyrosine residues and the subsequent coupling of these iodinated tyrosines.

• Disruption of Iodination: The first step in hormone synthesis is the oxidation of iodide ions (I−) to a more reactive iodine species (I2​ or HOI).[2] TPO catalyzes this oxidation, allowing the iodine to be incorporated onto tyrosine residues within the large glycoprotein thyroglobulin (Tg), a process known as organification.[2] Methimazole functions as a competitive substrate for TPO. It effectively traps the oxidized iodide, becoming iodinated itself and thereby preventing the iodination of thyroglobulin.[18] This action directly blocks the formation of the hormone precursors monoiodotyrosine (MIT) and diiodotyrosine (DIT).
• Inhibition of Coupling: Following organification, TPO catalyzes the coupling of two iodotyrosine residues to form the active thyroid hormones. The coupling of two DIT molecules forms thyroxine (T4​), while the coupling of one MIT and one DIT molecule forms triiodothyronine (T3​).[2] By binding irreversibly to the active site of TPO, methimazole disrupts this enzymatic coupling reaction, further halting the production of new thyroid hormones.[2]

A critical aspect of this mechanism is that methimazole only inhibits the synthesis of new hormones. It does not inactivate existing T4​ and T3​ that are already circulating in the blood or stored as colloid within the thyroid follicles.[2] The thyroid gland typically maintains a substantial reserve of pre-formed hormone, sufficient for several weeks. Consequently, the clinical effects of methimazole therapy, such as the amelioration of hyperthyroid symptoms, are not immediate. A noticeable therapeutic response typically takes several weeks to manifest, as the existing stores of thyroid hormone must first be depleted before the impact of inhibited synthesis becomes clinically apparent.[7]

3.2. Secondary and Potential Mechanisms

Beyond its primary action on TPO, methimazole may exert other effects that contribute to its therapeutic profile, particularly in the context of autoimmune thyroid disease.

• Immunomodulation in Graves' Disease: Graves' disease, the most common cause of hyperthyroidism, is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSIs) that activate the TSH receptor.[9] Emerging evidence suggests that methimazole may have immunomodulatory properties. Studies have shown that treatment with methimazole can lead to a decrease in the percentage of pro-inflammatory T-helper 17 (Th17) lymphocytes and a corresponding increase in immuno-suppressive T-regulatory (Treg) cells.[13] This shift in the Th17/Treg balance could theoretically dampen the underlying autoimmune attack on the thyroid. Furthermore, some research indicates a reduction in levels of other immune molecules, such as anti-TSH receptor antibodies and intracellular adhesion molecule 1, over the course of therapy.[2] It remains an area of investigation whether these immune effects are a direct pharmacological action of the drug or an indirect consequence of restoring a euthyroid state, which itself can modulate immune function.[2] This potential disease-modifying activity may provide a rationale for the observed clinical benefit of long-term methimazole therapy, which has been shown to induce higher rates of durable remission compared to shorter treatment courses.[9] The extended therapy may allow sufficient time for these immunomodulatory effects to re-establish immune tolerance.
• Free Radical Scavenging: In non-clinical settings, methimazole has been shown to act as a scavenger for free radicals, such as the hydroxyl radical (•OH).[7] While this property is utilized in organic chemistry research, its clinical relevance to the treatment of hyperthyroidism has not been established.

Section 4: Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

4.1. Absorption

Following oral administration, methimazole is rapidly and extensively absorbed from the gastrointestinal tract.[2] It demonstrates high absolute bioavailability, with studies reporting a mean of 93%.[7] Peak plasma concentrations (

Cmax​) are generally achieved within 1 to 2 hours post-administration.[2] The absorption of methimazole is not significantly affected by the presence of food, which provides flexibility in dosing and allows for consistent administration regardless of meal timing.[2]

4.2. Distribution

A defining pharmacokinetic feature of methimazole is its lack of significant binding to plasma proteins; it circulates primarily as a free, unbound drug in the serum.[7] This allows for ready distribution into tissues. The drug is known to be actively concentrated within its target organ, the thyroid gland, which contributes to its prolonged duration of action.[22] Importantly for clinical considerations in special populations, methimazole readily crosses the placental barrier and is also distributed into breast milk.[12]

4.3. Metabolism

Methimazole undergoes extensive hepatic metabolism, which is the primary route of its clearance from the body.[2]

• Enzyme Systems: The metabolic conversion of methimazole is principally mediated by two major enzyme systems: the Cytochrome P450 (CYP) system and the Flavin-containing monooxygenase (FMO) system.[19] In vitro studies have identified several specific CYP isoenzymes that are involved, including CYP1A2, CYP2C9, CYP2C19, and CYP3A4.[2] Methimazole itself has been shown to be a potent and nonspecific inhibitor of multiple CYP enzymes, particularly after preincubation, suggesting the potential for metabolism-based drug interactions.[13]
• Metabolites: The biotransformation of methimazole yields several metabolites. One of the earliest identified is 3-methyl-2-thiohydantoin, which may retain some antithyroid activity and could contribute to the overall therapeutic effect.[19] The process of metabolism, however, also carries toxicological implications. The same enzymatic pathways responsible for clearing the drug are believed to generate reactive metabolites that mediate its rare but serious hepatotoxicity. Metabolites such as glyoxal and N-methylthiourea, which are products of a dihydrodiol intermediate, have established cytotoxicity.[19] Furthermore, sulfenic and sulfinic acid derivatives, which may arise from direct oxidation of methimazole via the FMO system, are thought to be the ultimate toxicants responsible for methimazole-induced liver injury.[19] This establishes a direct link between the necessary metabolic clearance of the drug and the intrinsic risk of organ toxicity.

4.4. Excretion

The primary route of elimination for methimazole and its metabolites is via renal excretion into the urine.[2] A relatively small fraction of the administered dose, between 7% and 12%, is excreted as the unchanged parent drug.[2] The plasma elimination half-life of methimazole is relatively short, typically reported to be in the range of 4 to 6 hours.[2] This short half-life, however, belies its much longer duration of pharmacodynamic action (36 to 72 hours).[19] This discrepancy is explained by the drug's accumulation and retention within the thyroid gland, where it can exert its inhibitory effect on TPO long after plasma levels have declined. This pharmacokinetic property provides the rationale for effective once- or twice-daily dosing regimens in clinical practice, which can improve patient adherence. Some pharmacokinetic studies have described a biphasic elimination pattern, with a longer terminal half-life (

T1/2β​) of up to 20 hours, which likely reflects this slow release from thyroid tissue.[26] Evidence also suggests that enterohepatic circulation may play a role in the overall elimination of the drug and its metabolites.[19]

Table 2: Key Pharmacokinetic Parameters of Methimazole

Parameter	Value / Description	Source(s)
Bioavailability	~93% (oral)	7
Time to Peak (Tmax​)	1–2 hours	2
Plasma Protein Binding	None / Negligible	7
Primary Metabolism Site	Liver	2
Key Metabolizing Enzymes	Cytochrome P450 (CYP1A2, CYP2C9, CYP3A4); FMO	2
Elimination Half-life	4–6 hours (plasma); may have a longer terminal phase (~20 hours)	7
Route of Excretion	Primarily renal (urine)	2

Section 5: Clinical Applications and Therapeutic Efficacy

5.1. Primary Indication: Hyperthyroidism

Methimazole is a first-line therapy for hyperthyroidism resulting from Graves' disease or toxic multinodular goiter.[4] It is particularly indicated for patients in whom more definitive treatments like surgery or RAI are not appropriate or are deferred.[4]

• Graves' Disease Management: In Graves' disease, methimazole is used to control the overproduction of thyroid hormones, with the ultimate goal of inducing a lasting remission of the underlying autoimmune process.[9] Historically, antithyroid drugs were often viewed as a temporary measure or a "bridge" to ablative therapy. However, recent evidence has prompted a potential paradigm shift in this approach. A landmark randomized trial demonstrated that long-term methimazole therapy (60-120 months) resulted in a significantly lower relapse rate (17%) compared to the standard short-term course of 18-24 months (56%).[9] This finding suggests that for a substantial portion of patients, extended medical therapy may function as a definitive treatment in its own right, offering a viable alternative to irreversible thyroid ablation and the subsequent lifelong requirement for hormone replacement therapy.

5.2. Adjunctive Therapy

Methimazole plays a crucial adjunctive role in preparing patients for definitive hyperthyroidism treatments.

• Preparation for Thyroidectomy: It is standard practice to use methimazole to render a hyperthyroid patient euthyroid before surgery.[4] A course of therapy, typically for 1 to 2 months, normalizes the metabolic state and significantly reduces the perioperative risks, particularly the risk of a thyrotoxic crisis (thyroid storm) precipitated by surgical manipulation of the gland.[4]
• Preparation for Radioactive Iodine (RAI) Therapy: Methimazole is frequently used to ameliorate the symptoms of hyperthyroidism before and after the administration of RAI.[4] Pre-treatment is especially considered for elderly patients and those with severe hyperthyroidism or significant comorbidities (e.g., cardiovascular disease), as these individuals are at a higher risk of complications from a potential transient worsening of thyrotoxicosis that can occur after RAI administration.[4] To ensure the therapeutic efficacy of RAI, which relies on the thyroid gland's uptake of iodine, methimazole must be discontinued prior to treatment. Clinical guidelines typically recommend stopping methimazole 3 to 7 days before RAI administration and restarting it 3 to 7 days after, with a subsequent taper as the ablative effects of the radiation take hold.[4]

5.3. Acute Management

In the setting of a thyrotoxic crisis or thyroid storm—a life-threatening exacerbation of hyperthyroidism—methimazole is a key component of the multidrug treatment regimen.[4] It is administered to block the synthesis of new thyroid hormones. To prevent the newly synthesized hormones from being released, it is crucial to initiate methimazole therapy before the administration of iodide solutions (e.g., potassium iodide), which would otherwise provide more substrate for hormone production.[4]

5.4. Off-Label Use

Methimazole is also used off-label for the management of hyperthyroidism caused by a toxic adenoma (a single, autonomously functioning thyroid nodule).[4] In this context, it is typically used to control symptoms and normalize thyroid function as a bridge to definitive treatment with RAI or surgery, as medical therapy does not induce remission in nodular thyroid disease.[4]

Section 6: Dosage, Administration, and Monitoring

6.1. Adult Dosing

The oral dosage of methimazole for adults is stratified based on the severity of hyperthyroidism.

• Initial Dose: For mild hyperthyroidism, the typical starting dose is 15 mg per day. For moderately severe cases, the dose is increased to 30 to 40 mg per day. In cases of severe hyperthyroidism, an initial dose of 60 mg per day may be required.[12]
• Maintenance Dose: Therapy is continued at the initial dose until the patient becomes clinically and biochemically euthyroid, a process that usually takes 4 to 12 weeks.[29] Once euthyroidism is achieved, the dose is gradually reduced to a maintenance level, typically ranging from 5 to 15 mg per day, to maintain normal thyroid function.[12]

6.2. Pediatric Dosing

For pediatric patients, the dosage of methimazole is based on body weight.

• Initial Dose: The recommended initial daily dose is 0.4 mg/kg of body weight.[4]
• Maintenance Dose: The maintenance dosage is approximately half of the initial dose, or 0.2 mg/kg per day.[4] Doses in children are adjusted based on clinical response and regular monitoring of thyroid function tests.

6.3. Administration

Methimazole is available as 5 mg and 10 mg oral tablets.[12] The manufacturer recommends that the total daily dosage be administered in three equally divided doses at approximately 8-hour intervals to maintain steady drug levels.[12] However, due to the drug's long intrathyroidal duration of action, once-daily dosing is a common and effective practice that may enhance patient adherence.[29]

6.4. Therapeutic Monitoring

Close monitoring is essential for the safe and effective use of methimazole.

• Thyroid Function Tests: Thyroid function, including serum thyrotropin (TSH) and free thyroxine (free T4​) levels, should be monitored periodically throughout therapy.[12] Once the initial symptoms of hyperthyroidism have resolved, a rising serum TSH level is an indicator that the patient is becoming iatrogenically hypothyroid, signaling the need for a reduction in the methimazole maintenance dose.[5] It is important for clinicians and patients to be aware that biotin (Vitamin B7) supplements can interfere with the immunoassays used for thyroid function testing; these supplements should be discontinued at least two days before blood is drawn for these tests.[32]
• Safety Monitoring: Due to the risk of hypoprothrombinemia and bleeding, the prothrombin time (PT/INR) should be monitored, especially before any surgical procedures.[2] Most importantly, patients must be educated to immediately report any signs or symptoms of illness, particularly fever, sore throat, or general malaise. The onset of such symptoms should prompt an immediate complete blood count (CBC) with differential to rule out the development of agranulocytosis.[5]

Table 3: Recommended Dosing Regimens for Hyperthyroidism

Patient Population	Disease Severity	Initial Daily Dose	Maintenance Daily Dose	Administration Notes	Source(s)
Adult	Mild	15 mg	5–15 mg	Total daily dose typically given in 3 divided doses every 8 hours. Once-daily dosing is also a common practice.	12
	Moderately Severe	30–40 mg	5–15 mg		12
	Severe	60 mg	5–15 mg		12
Pediatric	All Severities	0.4 mg/kg	Approx. 0.2 mg/kg (half of initial dose)	Total daily dose given in 3 divided doses every 8 hours. Dose is based on body weight.	12

Section 7: Safety Profile, Adverse Reactions, and Toxicology

7.1. Overview of Adverse Effects

The safety profile of methimazole is well-characterized, with most adverse reactions being minor and self-limiting. However, the potential for rare but life-threatening toxicities necessitates vigilant monitoring and patient education.[5]

Table 4: Categorized Adverse Reactions with Estimated Frequencies

Category / System Organ Class	Frequency	Specific Adverse Reactions	Source(s)
Dermatologic	Common	Skin rash, pruritus (itching), urticaria (hives)	7
	Common	Abnormal hair loss (alopecia)	5
Gastrointestinal	Common	Nausea, vomiting, upset stomach (epigastric distress)	5
	Common	Loss of taste (ageusia) or metallic taste	7
Musculoskeletal	Common	Arthralgia (joint pain)	5
Nervous System	Uncommon	Headache, dizziness, drowsiness, paresthesia (tingling/numbness)	5
General	Uncommon	Edema (swelling), fever	5
Hematologic	Rare	Agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, hypoprothrombinemia	5
Hepatic	Rare	Hepatotoxicity, cholestatic jaundice, acute liver failure	5
Immunologic / Systemic	Rare	ANCA-positive vasculitis, lupus-like syndrome, Stevens-Johnson syndrome, insulin autoimmune syndrome	5
Endocrine	Dose-dependent	Iatrogenic Hypothyroidism	5
Gastrointestinal	Rare	Acute pancreatitis	7

7.2. In-Depth Analysis of Major Toxicities

• Agranulocytosis: This is the most feared idiosyncratic reaction to methimazole. It is a potentially fatal condition characterized by a severe reduction in the absolute neutrophil count, leaving the patient profoundly susceptible to infection.[5] The onset can be sudden, occurring within hours to days of starting therapy or even after months of stable treatment.[36] The risk appears to be dose-related, increasing in patients over 40 years of age and those receiving daily doses greater than 40 mg.[22] Given the rapid onset and severe consequences, routine blood count monitoring is not considered effective for early detection. The cornerstone of management is patient education. All patients initiating methimazole must be rigorously counseled to immediately stop the drug and seek medical attention if they develop any symptoms of infection, especially fever or a sore throat.[5] If agranulocytosis is confirmed by a CBC, methimazole must be permanently discontinued, and supportive care, including broad-spectrum antibiotics, should be initiated.[5]
• Hepatotoxicity: Methimazole can cause liver injury, although the risk of severe or fatal hepatotoxicity is notably lower than that associated with PTU.[5] The typical presentation is cholestatic jaundice, which may be accompanied by symptoms such as anorexia, pruritus, and right upper quadrant pain.[27] The injury can progress to acute liver failure in rare cases. Patients should be advised to report any such symptoms, and liver function tests should be performed if hepatic dysfunction is suspected. The drug should be promptly discontinued if there is clinically significant evidence of liver injury, such as hepatic transaminase levels exceeding three times the upper limit of normal.[5]
• Teratogenicity and Use in Pregnancy: The use of methimazole during the first trimester of pregnancy presents a significant clinical challenge due to its association with a specific pattern of congenital malformations, sometimes referred to as methimazole embryopathy.[5] These rare but serious birth defects include aplasia cutis congenita (a localized absence of skin, typically on the scalp), craniofacial anomalies such as choanal atresia (blockage of the posterior nasal passage), and gastrointestinal malformations like esophageal atresia and omphalocele.[7] This distinct teratogenic risk is the primary reason that PTU, despite its own safety concerns for the mother, is the preferred antithyroid drug during the first trimester of pregnancy.[6] This creates a critical clinical paradox: the drug that is generally safer for the mother (methimazole, with its lower risk of fatal hepatotoxicity) is more dangerous for the fetus during the critical period of organogenesis. Conversely, the drug that is more dangerous for the mother (PTU) is considered safer for the fetus during this same window. This conflict is resolved through a dynamic management strategy: using PTU for the first trimester and then switching the patient to methimazole for the second and third trimesters, by which time the primary risk of teratogenesis has passed.

7.3. Iatrogenic Hypothyroidism

A predictable consequence of methimazole therapy is the potential for over-treatment, leading to iatrogenic hypothyroidism.[5] Symptoms include fatigue, weight gain, constipation, and cold intolerance.[32] This is not considered a toxic effect but rather an extension of the drug's therapeutic action. It is managed through careful dose titration guided by regular monitoring of TSH and free

T4​ levels to maintain the patient in a euthyroid state.[5]

Section 8: Contraindications, Warnings, and Drug Interactions

8.1. Contraindications

Methimazole is absolutely contraindicated in patients with a known hypersensitivity to the drug or any of its components.[12] Due to the established risk of teratogenicity, it is considered relatively contraindicated during the first trimester of pregnancy, with PTU being the preferred alternative.[5] While the manufacturer's labeling lists breastfeeding as a contraindication, this is a point of debate, as several prominent medical organizations, including the American Academy of Pediatrics (AAP), consider it compatible with nursing under careful monitoring.[24]

8.2. Warnings and Precautions

• Hematologic: The drug should be used with caution in patients with pre-existing blood dyscrasias or bone marrow depression. Vigilant monitoring for signs of agranulocytosis, aplastic anemia, and thrombocytopenia is required.[27]
• Hepatic: Caution is advised when prescribing methimazole to patients with pre-existing liver disease.[27]
• Bleeding Risk: Methimazole may cause hypoprothrombinemia and increase the risk of bleeding. Prothrombin time (PT/INR) should be monitored, particularly before surgical procedures.[2]
• Vasculitis: Rare cases of Antineutrophil Cytoplasmic Autoantibody (ANCA)-positive vasculitis have been reported. The drug should be discontinued if vasculitis develops.[5]

8.3. Drug-Drug Interactions

Methimazole is subject to several clinically significant drug-drug interactions. A crucial category of these interactions is not a direct result of methimazole's pharmacology but is an indirect, physiology-mediated consequence of restoring the patient to a euthyroid state. The hypermetabolic state of hyperthyroidism leads to increased hepatic clearance of many drugs. As methimazole normalizes thyroid function, the clearance of these concomitant medications slows to a normal rate. If their doses are not adjusted downward, their plasma concentrations can rise, leading to potential toxicity. This applies particularly to beta-blockers, digoxin, and theophylline.[12]

Table 5: Significant Drug-Drug Interactions (Categorized by Severity and Mechanism)

Interacting Agent(s)	Severity	Mechanism and Clinical Consequence	Source(s)
Sodium Iodide I-131	Major	Pharmacodynamic Antagonism: Methimazole blocks the uptake and organification of iodine by the thyroid gland, which will reduce the efficacy of therapeutic radioactive iodine. Methimazole should be stopped 3–7 days prior to RAI therapy.	29
Carbamazepine, Clozapine, Propylthiouracil	Major	Pharmacodynamic Synergism: These agents are also known to cause myelosuppression. Concomitant use with methimazole produces an additive risk of developing severe agranulocytosis. Combinations should generally be avoided.	24
Oral Anticoagulants (e.g., Warfarin)	Moderate	Inhibition of Vitamin K Activity: Methimazole may have anti-vitamin K activity, potentiating the effect of oral anticoagulants and increasing the risk of bleeding. Closer monitoring of PT/INR is required, especially during dose initiation and adjustment.	12
Beta-Blockers (e.g., Propranolol, Metoprolol)	Moderate	Physiology-Mediated (Altered Clearance): Hyperthyroidism increases the clearance of beta-blockers. As methimazole restores euthyroidism, clearance decreases, leading to higher plasma levels and increased risk of bradycardia/hypotension. Dose reduction is often necessary.	12
Digoxin	Moderate	Physiology-Mediated (Altered Clearance): Serum digoxin levels may increase as a hyperthyroid patient becomes euthyroid. A reduction in the digoxin dosage may be required to avoid toxicity.	12
Theophylline	Moderate	Physiology-Mediated (Altered Clearance): Theophylline clearance is increased in hyperthyroidism and decreases as the patient becomes euthyroid. A reduced dose of theophylline may be needed to prevent toxicity.	12

Section 9: Use in Special Populations

9.1. Pregnancy and Lactation

The use of methimazole in pregnancy and lactation is complex and requires careful risk-benefit assessment.

• Pregnancy: As extensively discussed, methimazole is a known teratogen during the first trimester, associated with a specific pattern of congenital defects.[5] Therefore, current clinical guidelines recommend using propylthiouracil (PTU) for the management of maternal hyperthyroidism during the first trimester.[6] After the first trimester, when the risk of organogenesis is largely complete, it is often recommended to switch the patient from PTU back to methimazole. This change is made to minimize the mother's exposure to PTU's higher risk of severe hepatotoxicity.[6] Throughout pregnancy, it is imperative to use the lowest possible dose of the antithyroid drug to maintain maternal thyroid function at the upper end of the normal range, thereby controlling the disease while minimizing fetal exposure.[20]
• Lactation: Methimazole is excreted into breast milk.[7] While the manufacturer's labeling contraindicates its use during breastfeeding, this stance is not universally supported.[24] Major professional bodies, including the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP), have stated that methimazole is compatible with nursing, provided the infant's thyroid function is monitored.[24] The decision to breastfeed while taking methimazole should be made in consultation with the patient, weighing the benefits of breastfeeding against the potential risks to the infant.

9.2. Pediatrics

Methimazole is considered the antithyroid drug of choice for the treatment of hyperthyroidism in children.[4] This preference is a direct result of post-marketing reports that have linked PTU to a higher risk of severe and fatal liver injury in the pediatric population.[5] The efficacy and safety of methimazole in children are well-established. Dosing is calculated based on body weight and requires careful titration and monitoring to achieve and maintain euthyroidism.[12]

9.3. Geriatrics

No specific information is available on age-related differences in the effects of methimazole in geriatric patients.[27] However, elderly patients are more likely to have comorbidities (e.g., cardiovascular disease) and be on polypharmacy, increasing the importance of monitoring for adverse effects and drug interactions. Pre-treatment with methimazole before RAI therapy is particularly important in this population to mitigate the risks of worsening hyperthyroidism.[4]

Section 10: Veterinary Applications

10.1. Treatment of Feline Hyperthyroidism

Methimazole is the most commonly prescribed medication for the management of hyperthyroidism in cats, a frequent endocrine disorder in older felines.[7] Its use is well-established in veterinary medicine, with several FDA-approved formulations available, including Felimazole® (coated oral tablets) and Felanorm® (oral solution).[40]

10.2. Administration and Monitoring

The medication can be administered orally as tablets or a solution.[40] For cats that are difficult to medicate orally, it can be compounded by a specialty pharmacy into a transdermal gel that is applied to the hairless skin of the inner ear flap.[40] As in humans, methimazole manages the condition by inhibiting hormone synthesis but does not provide a cure; therefore, therapy is typically lifelong.[40] Regular monitoring of the cat's thyroid hormone levels (total

T4​) is necessary to ensure adequate control and to avoid inducing hypothyroidism.[41]

10.3. Clinical Considerations

A significant challenge in treating feline hyperthyroidism is its complex interplay with chronic kidney disease (CKD), which is also common in older cats. The hyperthyroid state induces a high cardiac output and increased renal blood flow, which can artificially improve glomerular filtration rate (GFR) and mask the presence or severity of underlying CKD.[41] When methimazole treatment normalizes thyroid function, the renal blood flow returns to normal. This can "unmask" pre-existing CKD, leading to a clinically apparent decline in renal function.[41] This phenomenon requires veterinarians to perform a delicate balancing act, carefully titrating the methimazole dose to control hyperthyroidism without causing a precipitous decline in kidney function.

Section 11: Conclusion and Clinical Perspective

Methimazole is a potent, effective, and well-established antithyroid agent that remains a fundamental tool in the management of hyperthyroidism. Its position as the first-line pharmacotherapy for most patients is firmly secured by its more favorable safety profile regarding severe hepatotoxicity when compared to propylthiouracil. Its utility extends from long-term management of Graves' disease, where emerging evidence supports extended therapy to promote durable remission, to its essential adjunctive role in preparing patients for definitive treatments like surgery and radioactive iodine ablation.

However, the therapeutic benefits of methimazole are balanced by a profile of rare but significant risks that demand clinical vigilance. The potential for life-threatening agranulocytosis mandates comprehensive patient education on its warning signs, while its established first-trimester teratogenicity dictates specific management strategies in pregnancy. The effective and safe use of methimazole is therefore contingent upon a deep understanding of its pharmacology, careful patient selection, appropriate dosing and monitoring, and a proactive approach to managing its potential toxicities and complex drug interactions. When wielded with this expertise, methimazole is an invaluable medication that can safely restore euthyroidism and dramatically improve the quality of life for patients with hyperthyroidism.

Works cited

1. Methimazole | C4H6N2S | CID 1349907 - PubChem, accessed September 13, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Methimazole
2. Methimazole - StatPearls - NCBI Bookshelf, accessed September 13, 2025, https://www.ncbi.nlm.nih.gov/books/NBK545223/
3. Methimazole | 60-56-0 - ChemicalBook, accessed September 13, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9220870.htm
4. Methimazole Monograph for Professionals - Drugs.com, accessed September 13, 2025, https://www.drugs.com/monograph/methimazole.html
5. Tapazole (Methimazole): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 13, 2025, https://www.rxlist.com/tapazole-drug.htm
6. Reports of severe liver injury prompt black box warning and new recommendations for propylthiouracil use - Managed Healthcare Executive, accessed September 13, 2025, https://www.managedhealthcareexecutive.com/view/reports-severe-liver-injury-prompt-black-box-warning-and-new-recommendations-propylthiouracil-use
7. Thiamazole - Wikipedia, accessed September 13, 2025, https://en.wikipedia.org/wiki/Thiamazole
8. Methimazole: Detailed Review on its Transformative R&D Success ..., accessed September 13, 2025, https://synapse.patsnap.com/blog/methimazole-detailed-review-on-its-transformative-randd-success-mechanism-of-action-and-drug-targets
9. What patients with Graves' disease should stay on methimazole longer? - American Thyroid Association, accessed September 13, 2025, https://www.thyroid.org/patient-thyroid-information/ct-for-patients/october-2024/vol-17-issue-10-p-9-10/
10. FDA Slaps Black Box Warning on Hyperthyroidism Drug - CD&L - Carey Danis & Lowe, accessed September 13, 2025, https://careydanis.com/blog/fda_slaps_black_box_warning_on/
11. FDA Drug Safety Communication: New Boxed Warning on severe ..., accessed September 13, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-new-boxed-warning-severe-liver-injury-propylthiouracil
12. METHIMAZOLE TABLETS Label - accessdata.fda.gov, accessed September 13, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/040350s016lbl.pdf
13. CHEBI:50673 - methimazole - EMBL-EBI, accessed September 13, 2025, https://www.ebi.ac.uk/chebi/searchId.do?chebiId=50673
14. Methimazole - brand name list from Drugs.com, accessed September 13, 2025, https://www.drugs.com/ingredient/methimazole.html
15. Methimazole | CAS 60-56-0 | SCBT - Santa Cruz Biotechnology, accessed September 13, 2025, https://www.scbt.com/p/methimazole-60-56-0
16. Methimazole - OEHHA - CA.gov, accessed September 13, 2025, https://oehha.ca.gov/chemicals/methimazole
17. Methimazole - PubMed, accessed September 13, 2025, https://pubmed.ncbi.nlm.nih.gov/31424807/
18. Methimazole (NSC 38608, CAS Number: 60-56-0) | Cayman Chemical, accessed September 13, 2025, https://www.caymanchem.com/product/23718/methimazole
19. Methimazole: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 13, 2025, https://go.drugbank.com/drugs/DB00763
20. Methimazole: Package Insert / Prescribing Information - Drugs.com, accessed September 13, 2025, https://www.drugs.com/pro/methimazole.html
21. What is the mechanism of Methimazole? - Patsnap Synapse, accessed September 13, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-methimazole
22. methimazole, accessed September 13, 2025, https://www.glowm.com/resources/glowm/cd/pages/drugs/m030.html
23. Pharmacokinetic properties and bioavailability of methimazole - PubMed, accessed September 13, 2025, https://pubmed.ncbi.nlm.nih.gov/4042519/
24. Northyx, Tapazole (methimazole) dosing, indications, interactions, adverse effects, and more, accessed September 13, 2025, https://reference.medscape.com/drug/tapazole-methimazole-342734
25. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes - PubMed, accessed September 13, 2025, https://pubmed.ncbi.nlm.nih.gov/9172960/
26. Pharmacokinetics of Methimazole in Normal Subjects and ... - J-Stage, accessed September 13, 2025, https://www.jstage.jst.go.jp/article/endocrj1954/33/5/33_5_605/_article
27. Methimazole (oral route) - Side effects & dosage - Mayo Clinic, accessed September 13, 2025, https://www.mayoclinic.org/drugs-supplements/methimazole-oral-route/description/drg-20073004
28. Methimazole: MedlinePlus Drug Information, accessed September 13, 2025, https://medlineplus.gov/druginfo/meds/a682464.html
29. Methimazole: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed September 13, 2025, https://www.medcentral.com/drugs/monograph/7251-382464/methimazole-oral
30. Methimazole - WikEM, accessed September 13, 2025, https://wikem.org/wiki/Methimazole
31. Methimazole Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 13, 2025, https://www.drugs.com/dosage/methimazole.html
32. Methimazole: Uses & Side Effects - Cleveland Clinic, accessed September 13, 2025, https://my.clevelandclinic.org/health/drugs/19402-methimazole-tablets
33. Adverse Events Associated with Methimazole Therapy of Graves' Disease in Children - PMC, accessed September 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2833412/
34. What are the most common side effects of methimazole and their ..., accessed September 13, 2025, https://www.droracle.ai/articles/240826/create-a-table-indicating-the-relative-frequencies-are-the-most-common-side-effects
35. Methimazole Uses, Side Effects & Warnings - Drugs.com, accessed September 13, 2025, https://www.drugs.com/mtm/methimazole.html
36. Methimazole Side Effects: Common, Severe, Long Term - Drugs.com, accessed September 13, 2025, https://www.drugs.com/sfx/methimazole-side-effects.html
37. Methimazole: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 13, 2025, https://www.rxlist.com/methimazole/generic-drug.htm
38. www.mayoclinic.org, accessed September 13, 2025, https://www.mayoclinic.org/drugs-supplements/methimazole-oral-route/description/drg-20073004#:~:text=Check%20with%20your%20doctor%20right%20away%20if%20you%20have%20constipation,or%20unusual%20tiredness%20or%20weakness.
39. Methimazole Disease Interactions - Drugs.com, accessed September 13, 2025, https://www.drugs.com/disease-interactions/methimazole.html
40. Methimazole | VCA Animal Hospitals, accessed September 13, 2025, https://vcahospitals.com/know-your-pet/methimazole
41. Hyperthyroidism Medication for Cats (Methimazole) - Veterinary Partner - VIN, accessed September 13, 2025, https://veterinarypartner.vin.com/doc/?id=4951394
42. Hyperthyroidism in Cats—Two FDA-Approved Drugs Available to Treat It, accessed September 13, 2025, https://www.fda.gov/animal-veterinary/animal-health-literacy/hyperthyroidism-cats-two-fda-approved-drugs-available-treat-it
43. FDA Approves First Generic Methimazole Coated Tablets for Treating Hyperthyroidism in Cats, accessed September 13, 2025, https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-generic-methimazole-coated-tablets-treating-hyperthyroidism-cats
44. FDA approves first generic drug for hyperthyroidism in cats, accessed September 13, 2025, https://www.avma.org/news/fda-approves-first-generic-drug-hyperthyroidism-cats
45. FDA Approves First Generic Methimazole for Treating Hyperthyroidism in Cats, accessed September 13, 2025, https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-generic-methimazole-treating-hyperthyroidism-cats